Pyrrolidine aryl-ether as NK3 receptor antagonists

US7812021B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Philippe Jablonski · Steinbrunn-le-Haut, FR
• Kenichi Kawasaki · Yokohama, JP
• Henner Knust · Rheinfelden (Baden), DE
• Anja Limberg · Penzberg, DE
• Matthias Nettekoven · Weil am Rhein, DE
• Hasane Ratni · Habsheim, FR
• Claus Riemer · Glückstadt, DE
• Xihan Wu · Shanghai, CN

Key dates

• Filing date: Aug 21, 2008
• Grant date: Oct 12, 2010
• Expiry date: Aug 21, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/10
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to a compound of general formulawherein are as defined herein or to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. The compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).